PRETHERAPY BOTULINUM TOXIN TO REDUCE RADIATION-RELATED XEROSTOMIA IN HEAD AND NECK CANCER

Registry ID

MP-05-2025-4215

Source registry

HEALTH_CANADA

Status

Pending

Study type

INTERVENTIONAL

Sponsor

RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE

Last update

2026-02-03

Conditions

• HEAD AND NECK CANCER
• XEROSTOMIA

Related clinical trials

• LONG-TERM FOLLOW-UP OF AAV2-HAQP1 GENE THERAPY IN PARTICIPANTS WITH RADIATION-INDUCED LATE XEROSTOMIA
• A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO DETERMINE THE EFFICACY AND SAFETY OF AAV2-HAQP1 GENE THERAPY IN PARTICIPANTS WITH RADIATION-INDUCED LATE XEROSTOMIA
• A PHASE I/IB STUDY EVALUATING SINGLE-AGENT INAVOLISIB AND INAVOLISIB PLUS ATEZOLIZUMAB IN PIK3CA-MUTATED CANCERS
• PHASE 1/1B STUDY OF AKT INHIBITOR IPATASERTIB WITH CHEMORADIATION FOR LOCALLY ADVANCED HEAD AND NECK CANCER
• A PHASE 2, RANDOMIZED, OPEN-LABEL THREE-ARM CLINICAL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF LENVATINIB (E7080/MK-7902) IN COMBINATION WITH PEMBROLIZUMAB (MK-3475) VERSUS STANDARD OF CARE CHEMOTHERAPY AND LENVATINIB MONOTHERAPY IN PARTICIPANTS WITHRECURRENT/METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA (R/M HNSCC) THAT HAVE PROGRESSED AFTER PLATINUM THERAPY AND IMMUNOTHERAPY (PD-1/PD-L1 INHIBITORS) (LEAP-009)
• NOVEL MRI-GUIDED ULTRASOUND STIMULATED MICROBUBBLE RADIATION TREATMENT FOR PATIENTS WITH HEAD AND NECK CANCER

View on source registry